Respiratory Inhaler Devices Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Respiratory Inhaler Devices Market: By Product Type (Metered Dose Inhaler, Nebulizer, Dry Powder Inhaler), By Technology (Manually Operated Inhalers, Digitally Operated Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The respiratory inhaler devices market is expected to reach USD 41098 million by 2027 and will grow at a CAGR of 5.84% during the forecast period 2021 to 2027. Respiratory Inhaler Devices are the medical devices that deliver the medication to prevent or control the chronic obstructive pulmonary disease (COPD), asthma, and other respiratory disorders. Various types of respiratory inhaler devices are available in the market such as metered dose inhaler, dry powder inhaler, and nebulizer. Escalation in the number of industries led to an abnormal increase in environmental pollution that causes respiratory diseases such as COPD and asthma might propel the market. According to World Health Organization approximately 3 Mn deaths were observed in 2015 around the globe. Increase in the tobacco consumption majorly in middle and low income countries may causes respiratory disorders and which in turn drive the market. Moreover, most of the market players are focusing on the development of newer respiratory inhaler devices which are more convenient for drug administration.  Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies followed by market players for garnering larger revenue share in market. For instance, in April 2016, AstraZeneca received FDA approval for Bevepsi Aeresphere (glycopyrrolate and formoterol fumarate) inhalation aerosol used in chronic obstructive pulmonary disease (COPD). In addition, in January 2016, Novartis AG collaborated with Qualcomm, Inc. for the innovation of digital technology for Breezhaler inhaler used in the treatment of COPD. For instance, in August 2014, Sandoz received Mexico’s Health Authority (COFEPRIS) approval for the marketing of Airflusal Forspiro used in COPD. Middle East and Africa market driven by product launchings by the market players in Africa region. For instance, in January 2017, Cipla launched respiratory inhaler Synchrobreathe in South Africa. Moreover, increase in tobacco consumption and increase in pollution due to increasing the number of industries are anticipated to boost the market in the region.

Respiratory Inhaler Devices Market

MARKET SUMMARY
-
5.84% CAGR
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 5.84%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Respiratory Inhaler Devices Market

  • The report on global Respiratory Inhaler Devices Market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, technology, disease indication, distribution channel and geography.
  • Respiratory Inhaler Devices Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Cipla
  • Beximco Pharmaceuticals
  • Merck & Co.
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim
Respiratory Inhaler Devices Market

Drivers

Increase in the prevalence of COPD, asthma, and other respiratory disorder, technological advancements in respiratory inhaler devices, rapid industrialization and rise in smoking population are anticipated to fuel the market. Moreover, ease of administration of drug with respiratory inhaler devices, cost-effective of the products, and growing newborn babies and geriatric population who often exposed to one or the other respiratory disorders are anticipated to boost the respiratory inhaler devices market over the forecast period. However, adverse effects associated with drug inhalation, product recalls, lack of single effective inhalers for all types of disease, and lack of awareness about respiratory inhalers in underdeveloped countries expected to hamper the growth of the market over the forecast timeframe.


North-America got significant share

Respiratory Inhaler Devices Market

North America respiratory inhaler devices market is growing due to increase in the prevalence of respiratory disorders such as COPD (according to Centers for Disease Control and Prevention 2014, approximately 15.7 Mn Americans were diagnosed with COPD), high awareness about the respiratory inhalers, and technological advancements in the devices are anticipated to fuel the market. Europe respiratory inhaler devices market driven by increase in the prevalence of respiratory disorders such as COPD and asthma majorly in Sweden, Austria, Switzerland, Belgium, and Portugal, adoption of newer respiratory inhaler devices, and expansion of business by market players in the region. For instance, in November 2015 Sandoz launched AirFlu Sal Forspiro in UK. Asia Pacific market has a lucrative growth, which is attributed to increase in geriatric and newborn population, rise in health awareness, and growing pollution due to rapid industrialization in the region. Latin America respiratory inhaler devices market is poised to grow at significant rate owing to product approval in Latin America region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2021-2027
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Segmentation

Respiratory Inhaler Devices Market


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Cipla Ltd. (India)
  • Beximco Pharmaceuticals Ltd. (Bangladesh)
  • Merck & Co., Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Boehringer Ingelheim GmbH (Germany)
  • Koninklijke Philips N.V. (Netherlands)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • OMRON Healthcare Europe B.V. (Netherlands)
  • Novartis AG (Switzerland)
  • PARI Medical Holding GmbH (Germany)

Description

The respiratory inhaler devices market is expected to reach USD 41098 million by 2027 and will grow at a CAGR of 5.84% during the forecast period 2021 to 2027. Respiratory Inhaler Devices are the medical devices that deliver the medication to prevent or control the chronic obstructive pulmonary disease (COPD), asthma, and other respiratory disorders. Various types of respiratory inhaler devices are available in the market such as metered dose inhaler, dry powder inhaler, and nebulizer. Escalation in the number of industries led to an abnormal increase in environmental pollution that causes respiratory diseases such as COPD and asthma might propel the market. According to World Health Organization approximately 3 Mn deaths were observed in 2015 around the globe. Increase in the tobacco consumption majorly in middle and low income countries may causes respiratory disorders and which in turn drive the market. Moreover, most of the market players are focusing on the development of newer respiratory inhaler devices which are more convenient for drug administration.  Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies followed by market players for garnering larger revenue share in market. For instance, in April 2016, AstraZeneca received FDA approval for Bevepsi Aeresphere (glycopyrrolate and formoterol fumarate) inhalation aerosol used in chronic obstructive pulmonary disease (COPD). In addition, in January 2016, Novartis AG collaborated with Qualcomm, Inc. for the innovation of digital technology for Breezhaler inhaler used in the treatment of COPD. For instance, in August 2014, Sandoz received Mexico’s Health Authority (COFEPRIS) approval for the marketing of Airflusal Forspiro used in COPD. Middle East and Africa market driven by product launchings by the market players in Africa region. For instance, in January 2017, Cipla launched respiratory inhaler Synchrobreathe in South Africa. Moreover, increase in tobacco consumption and increase in pollution due to increasing the number of industries are anticipated to boost the market in the region.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX